These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24553726)

  • 61. Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
    Ho J; Ondos J; Ning H; Smith S; Kreisl T; Iwamoto F; Sul J; Kim L; McNeil K; Krauze A; Shankavaram U; Fine HA; Camphausen K
    PLoS One; 2013; 8(8):e70745. PubMed ID: 23940635
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
    Balducci M; Fiorentino A; De Bonis P; Chiesa S; Mangiola A; Mattiucci GC; D'Agostino GR; Frascino V; Mantini G; Alitto AR; Colosimo C; Anile C; Valentini V
    Strahlenther Onkol; 2013 Nov; 189(11):926-31. PubMed ID: 23974823
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
    Saito T; Sugiyama K; Ikawa F; Yamasaki F; Ishifuro M; Takayasu T; Nosaka R; Nishibuchi I; Muragaki Y; Kawamata T; Kurisu K
    World Neurosurg; 2017 Jan; 97():21-26. PubMed ID: 27693246
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
    Joo JD; Kim H; Kim YH; Han JH; Kim CY
    J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
    Wang TJ; Jani A; Estrada JP; Ung TH; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Isaacson SR; Cheng SK; McKhann GM; Bruce JN; Lassman AB; Sisti MB
    Neurosurgery; 2016 May; 78(5):676-82. PubMed ID: 26440447
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
    Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
    Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
    Stark AM; van de Bergh J; Hedderich J; Mehdorn HM; Nabavi A
    Clin Neurol Neurosurg; 2012 Sep; 114(7):840-5. PubMed ID: 22377333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognosis of patients with multifocal glioblastoma: a case-control study.
    Patil CG; Yi A; Elramsisy A; Hu J; Mukherjee D; Irvin DK; Yu JS; Bannykh SI; Black KL; Nuño M
    J Neurosurg; 2012 Oct; 117(4):705-11. PubMed ID: 22920963
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of a Time Delay for Concomitant Chemoradiation After Surgery for Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup Analysis According to the Extent of Tumor Resection.
    Ahn S; Park JS; Song JH; Jeun SS; Hong YK
    World Neurosurg; 2020 Jan; 133():e640-e645. PubMed ID: 31568907
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
    Raj S; Pandit PN; Kishor K
    Gulf J Oncolog; 2016 Jan; 1(20):6-11. PubMed ID: 27050173
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
    Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
    Rusthoven CG; Koshy M; Sher DJ; Ney DE; Gaspar LE; Jones BL; Karam SD; Amini A; Ormond DR; Youssef AS; Kavanagh BD
    JAMA Neurol; 2016 Jul; 73(7):821-8. PubMed ID: 27214765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
    Abrey LE
    Curr Neurol Neurosci Rep; 2005 May; 5(3):167-8. PubMed ID: 15865881
    [No Abstract]   [Full Text] [Related]  

  • 80. Glioblastoma management in the temozolomide era: have we improved outcome?
    Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP
    J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.